Latest Pharmaceutical Manufacturing News

Star Combo Pharma has reported a remarkable jump in profit for FY2025, driven by strong revenue growth and a settled insurance claim, while declaring its second dividend and planning production expansion.

Star Combo Pharma Limited reported a 7% increase in total revenue to $27.8 million for FY25, propelled by a 10% rise in its core OEM and Own Brands segment. The company’s profit before tax surged to $5.31 million, reflecting operational strength despite challenges in its Retail division.

IDT Australia Limited reported a strong 40.6% increase in revenue to $19.86 million for FY25, driven by growth in advanced therapies and contract disbursements. However, the company’s net loss widened to $8.06 million as it transitions from its ‘Rebuild Strategy’ to a new phase focused on sustainable profitability.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

IDT Australia announces the immediate resignation of CEO Paul McDonald, appointing Executive Chair Mark Simari to lead as the company reports a 40.6% revenue increase but a widening net loss for FY25.

Epsilon Healthcare has completed a $6.7 million sale and leaseback of its Southport manufacturing site, significantly reducing debt and securing long-term operational stability.

Clever Culture Systems advances its pharmaceutical market penetration with AstraZeneca’s full deployment and Novo Nordisk’s first order, while launching a new contact plate analysis module that doubles its APAS Independence system’s capabilities.

Epsilon Healthcare has emerged from voluntary administration with a stronger balance sheet, securing refinancing and preparing to launch its new pharmacy platform. Operational stability and strategic initiatives signal a turning point for the healthcare group.

IDT Australia has signed a memorandum with NASDAQ-listed Gelteq to establish a dedicated gel-based product manufacturing facility, marking a strategic expansion in pharmaceutical delivery technologies.

Clever Culture Systems has sold its APAS Independence instrument to Novo Nordisk for a comprehensive evaluation across the pharmaceutical giant’s manufacturing network, marking a key step in its global sales strategy.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.